Today’s 6 in the City segment features host Stephanie McCoy and guest Dr. Jordan Heimer, DMD, the Head of Restorative for ...
Newborn screening is transforming, as advances in genomic sequencing pave the way for earlier, more accurate diagnoses of ...
4h
Zacks.com on MSNBiotech Stock Roundup: BLUE Down on Update, News From GILD, TRDAIt was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and ...
Prime Bank PLC, in partnership with Bangladesh Insurance Academy (BIA), has recently conducted a three-day training course on ...
Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...
Jae Hyun Park, DMD, PhD, was selected to be the next editor-in-chief of the American Journal of Orthodontics and Dentofacial Orthopedics and AJO-DO Clinical Companion, effective June 1.
Mitchell: Officially, by the first birthday, or within six months of the first tooth’s coming in. The first appointment is ...
Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to ...
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...
Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transfo ...
Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results